Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma

Emerging evidence suggests receptor tyrosine kinase ALK as a promising therapeutic target in neuroblastoma. However, clinical trials reveal that a limited proportion of ALK-positive neuroblastoma patients experience clinical benefits from Crizotinib, a clinically approved specific inhibitor of ALK....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Chen, Kai, Lv, Fan, Xu, Guofeng, Zhang, Min, Wu, Yeming, Wu, Zhixiang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342791/
https://ncbi.nlm.nih.gov/pubmed/27732954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12513
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia